On August 25, SelectQuote (NASDAQ:SLQT) told investors that cash generation, not growth, is now the entire point of owning the stock. Fiscal 2026 revenue reached $1.62 billion, up 6% year over year, and operating cash flow climbed $44 million from the prior year. But the same release showed a fourth-quarter net loss of $16.8 million, a reversal from $12.9 million in net income a year earlier, and a fiscal 2027 guide that points meaningfully lower on the top line. That gap between the narrative and the numbers underneath it is worth sitting with.
The Pharmacy Engine Wakes Up
Healthcare Services, built around the company’s SelectRx pharmacy, generated $845 million in revenue for fiscal 2026, up 14% even as Inflation Reduction Act drug pricing changes cut into the segment starting in the back half of the year. That business exited the fourth quarter at an annualized adjusted EBITDA run rate of nearly $50 million, roughly double the $25 million it produced across the full year, and management expects those margins to keep expanding as more prescriptions route through the company’s Olathe, Kansas facility, which is already shipping about 30% more efficiently than its older sites.
Layered on top, SelectQuote identified more than $30 million in annualized run rate savings from AI-enabled enrollment tools and workflow automation. The Senior segment, meanwhile, held a 26% adjusted EBITDA margin for a fourth straight year in the mid-20% range, evidence that the agent-led distribution model keeps producing steady profit even when Medicare Advantage carriers shift benefits underneath it. Add in a commissions receivable balance north of $1 billion, and the company argues its underlying earnings power is bigger than its stock price reflects.
A Smaller Business Ahead
The guidance tells a different story. SelectQuote expects fiscal 2027 revenue of $1.35 billion to $1.45 billion, roughly 14% below fiscal 2026 at the midpoint, with Medicare Advantage approved policies projected to fall another 10% to 15% after already declining 4% this past year. Senior segment revenue already dropped 4% in fiscal 2026 to $576 million, partly because a major carrier partner pulled back its own marketing spending, a reminder of how much SelectQuote’s results depend on decisions made by insurers it does not control.
The Inflation Reduction Act will keep pressuring Healthcare Services revenue through fiscal 2027, with especially messy comparisons in the first half. SelectRx membership already moderated to 109,039 members and is expected to dip further before recovering. Underneath all of it sits $800 million in debt and preferred equity carrying a roughly 12% funding cost, translating into $45 million of annual cash interest that has to be paid regardless of how enrollment season goes. Management itself called the term life insurance market competitive on customer acquisition costs, a small but telling admission that not every corner of the business is running cleanly.
What The Smart Money Sees
Hedge fund ownership of SelectQuote rose from 13 funds to 21 quarter over quarter, which reads as building institutional conviction rather than funds heading for the exits. Short interest sits at just 1.16% of float, indicating little organized skepticism is betting against the stock right now. Yet the stock trades at a forward price-to-earnings ratio of 66.67 as of September 1, a multiple that already prices in a lot of the earnings growth management is promising for fiscal 2027 and beyond.
Two Very Different Stories
SelectQuote is asking investors to look past a 14% revenue decline and a swing to a quarterly net loss and focus instead on doubling operating cash flow to $60 million or more in fiscal 2027. For the bull case to hold, Healthcare Services margins need to actually double as promised, and the Kansas facility needs to keep delivering efficiency gains at scale. For the bear case to matter, Medicare Advantage policy declines would need to run deeper than guided or the IRA headwind would need to bite harder than management expects.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
